Octagon Capital Advisors’s Neurogene NGNE Stock Holding History

Octagon Capital Advisors’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-252,000	Closed	-$4.37M	–	32
2025 Q3	$4.37M	Sell	252,000 -51,000	-17%	-$1.02M	0.66%	23
2025 Q2	$4.53M	Hold	303,000	–	–	0.99%	25
2025 Q1	$3.55M	Hold	303,000	–	–	0.69%	34
2024 Q4	$6.93M	Buy	303,000 +288,000	+1,920%	+$10.7M	1.14%	27
2024 Q3	$629K	Buy	+15,000	New	+$582K	0.1%	40

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Octagon Capital Advisors's NGNE Position: Q4 2025 in Review

Octagon Capital Advisors sold out of Neurogene (NGNE) in Q4 2025, closing a stake of 252,000 shares — an estimated $4.37M sold.

Octagon Capital Advisors first reported a position in NGNE in Q3 2024 and held it in 5 quarters. The position peaked at $6.93M in Q4 2024. 93 funds tracked by Wall St. Rank hold NGNE as of Q4 2025.

Octagon Capital Advisors reported no remaining Neurogene position as of Q4 2025 after selling out during the quarter.
Octagon Capital Advisors sold 252,000 Neurogene shares in Q4 2025, an estimated $4.37M.
Octagon Capital Advisors first reported a position in Neurogene in Q3 2024 and held it in 5 quarters.
Octagon Capital Advisors's Neurogene position peaked at $6.93M in Q4 2024.
93 funds tracked by Wall St. Rank held Neurogene as of Q4 2025.

Based on Octagon Capital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.